Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma

Naqvi, Mariam; Choudhry, Shweta; Tsai, Hui Ju; Thyne, Shannon; Navarro, Daniel; Nazario, Sylvette; Rodríguez‐Santana, José; Casal, Jesus; Torres, Alfonso; Chapela, Rocío; Watson, H. Geoffrey; Meade, Kelley; Rodríguez-Cintrón, William; LeNoir, Michael A.; Avila, Pedro C.; Burchard, Esteban G.

doi:10.1016/j.jaci.2007.02.045

Cited by 71 publications

(55 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(23) Recently, other authors have reported that, among patients with asthma, mean FEV 1 is significantly lower in those with high IgE levels than in those with low IgE levels. (24) Among our patients, baseline FEV 1 was 53.9 ± 14.0% and 54.5±14.3% of predicted, respectively, in those with high and low total serum IgE levels (p = 0.79). Unlike the asthma subjects recruited in some other studies, our patients were not in remission.…”

Section: Resultsmentioning

confidence: 55%

Serum total IgE levels and total eosinophil counts: relationship with treatment response in patients with acute asthma

Razi

Moosavi

2010

J. bras. pneumol.

View full text Add to dashboard Cite

Objective: To determine whether serum total IgE levels and total eosinophil counts have any relationship with the response to routine pharmacological treatment in patients with acute asthma. Methods: A cross-sectional study involving 162 patients with acute asthma. Serum total IgE levels, peripheral blood cell counts and eosinophil counts were determined. The treatment was adjusted for each patient according to the severity of asthma. Spirometry was performed at baseline and two weeks after the treatment. The patients were divided into two groups: high IgE (≥100 IU/mL) and low IgE (<100 IU/mL). We compared the two groups in terms of the relationships between baseline values and final values (percentage change) for the following parameters: FEV 1 , FVC, FEF 25-75% , peripheral white blood cell counts and eosinophil counts. Results: There were no significant differences between the groups regarding the percentage changes of the studied parameters. Nor were there significant differences between the groups regarding FEV 1 , FVC, and FEF 25-75% (% of the predicted values) at baseline. Conclusions: On the basis of these findings, we conclude that serum total IgE levels, peripheral white blood cell counts and eosinophil counts cannot predict the response to the pharmacological treatment of patients with acute asthma.Keywords: Asthma/drug therapy; Eosinophils; Immunoglobulin E Resumo Objetivo: Determinar se há uma relação dos níveis de IgE total no soro e das contagens de eosinófilos com a resposta à farmacoterapia de rotina em pacientes com asma aguda. Métodos: Estudo transversal com 162 pacientes com asma aguda. Foram determinados os níveis séricos de IgE total, as contagens de células no sangue periférico e as contagens de eosinófilos. O tratamento foi ajustado individualmente de acordo com a gravidade da asma. Foi realizada espirometria antes do início do tratamento e duas semanas após seu término. Os pacientes foram divididos em dois grupos: alto nível de IgE (≥ 100 UI/mL) e baixo nível de IgE (< 100 UI/mL). Foram comparadas entre os dois grupos as relações das determinações basais e das alterações em percentual dos seguintes parâmetros: VEF, CVF, FEF 25-75% , contagem de células brancas no sangue periférico e contagem de eosinófilos. Resultados: Não houve diferenças significativas entre os grupos em relação às alterações em percentual dos parâ-metros estudados. Tampouco houve diferenças significativas entre os grupos em relação aos valores basais de VEF, CVF e FEF 25-75% , em % do predito. Conclusões: Com base nesses achados, concluímos que os níveis séricos de IgE total, as contagens de células brancas no sangue periférico e as contagens de eosinófilos não são preditores do tratamento farmacológico de pacientes com asma aguda.

show abstract

Section: Resultsmentioning

confidence: 55%

Serum total IgE levels and total eosinophil counts: relationship with treatment response in patients with acute asthma

Razi

Moosavi

2010

J. bras. pneumol.

View full text Add to dashboard Cite

show abstract

“…Total IgE concentration was more than twofold that previously reported in omalizumab trials [5,6], two-thirds of the children were polysensitised, onethird had food allergy, and rhinitis comorbidity was nearly constant. An elevated production of total IgE was demonstrated to be a marker of asthma severity in children [19] and was related to greater healthcare utilisation, altered lung function and airway hyperresponsiveness [20,21]. In contrast, such a severe allergic profile has not yet been clearly individualised as a risk group in problematic severe asthma either in previous cohorts [15,17] or in recent guidelines [2].…”

Section: Discussionmentioning

confidence: 99%

Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey

et al. 2013

View full text Add to dashboard Cite

Omalizumab has been shown to reduce exacerbation rates in moderate to severe allergic asthma. Our aim was to evaluate omalizumab efficacy and safety in a real-life setting in severe asthmatic children.104 children (aged 6-18 years), followed up in paediatric pulmonary tertiary care centres, were included at the beginning of omalizumab treatment. Asthma control levels, exacerbations, inhaled corticosteroid dose, lung function and adverse events were evaluated over 1 year.Children were characterised by allergic sensitisation to three or more allergens (66%), high IgE levels (mean 1125 kU?L -1 ), high rate of exacerbations (4.4 per year) and healthcare use during the previous year, and high inhaled corticosteroid dose (mean 703 mg equivalent fluticasone per day). Asthma control levels defined as good, partial or poor, improved from 0%, 18% and 82% at entry to 53%, 30% and 17% at week 20, and to 67%, 25% and 8% at week 52, respectively (p,0.0001). Exacerbation and hospitalisation rates dropped by 72% and 88.5%, respectively. At 12 months, forced expiratory volume in 1 s improved by 4.9% (p50.023), and inhaled corticosteroid dose decreased by 30% (p,0.001). Six patients stopped omalizumab for related significant adverse events.Omalizumab improved asthma control in children with severe allergic asthma and was generally well tolerated. The observed benefit was greater than that reported in clinical trials. @ERSpublications Omalizumab improves asthma control in children with severe allergic asthma and is generally well tolerated

show abstract

“…SC4 is 100% atopic, has the earliest age of asthma onset, longest disease duration, and severe disease, but normal FE NO and a high percentage of BAL lymphocytes. SC5, the youngest cluster, has high FE NO , a high percentage of African Americans (.50%), and, perhaps not surprisingly, the highest IgE levels (32)(33)(34). Although eosinophil levels are high, lung function does not differ from the "healthy" SC1.…”

Section: Clustering Of Subjectsmentioning

confidence: 93%

Gene Expression in Relation to Exhaled Nitric Oxide Identifies Novel Asthma Phenotypes with Unique Biomolecular Pathways

Modena

Tedrow

Milošević

et al. 2014

Am J Respir Crit Care Med

170

178

View full text Add to dashboard Cite

Rationale: Although asthma is recognized as a heterogeneous disease associated with clinical phenotypes, the molecular basis of these phenotypes remains poorly understood. Although genomic studies have successfully broadened our understanding in diseases such as cancer, they have not been widely used in asthma studies.Objectives: To link gene expression patterns to clinical asthma phenotypes.Methods: We used a microarray platform to analyze bronchial airway epithelial cell gene expression in relation to the asthma biomarker fractional exhaled nitric oxide (FE NO ) in 155 subjects with asthma and healthy control subjects from the Severe Asthma Research Program (SARP). Measurements and Main Results:We first identified a diverse set of 549 genes whose expression correlated with FE NO . We used k-means to cluster the patient samples according to the expression of these genes, identifying five asthma clusters/phenotypes with distinct clinical, physiological, cellular, and gene transcription characteristics-termed "subject clusters" (SCs). To then investigate differences in gene expression between SCs, a total of 1,384 genes were identified that highly differentiated the SCs at an unadjusted P value , 1026 . Hierarchical clustering of these 1,384 genes identified nine gene clusters or "biclusters," whose coexpression suggested biological characteristics unique to each SC. Although genes related to type 2 inflammation were present, novel pathways, including those related to neuronal function, WNT pathways, and actin cytoskeleton, were noted.Conclusions: These findings show that bronchial epithelial cell gene expression, as related to the asthma biomarker FE NO , can identify distinct asthma phenotypes, while also suggesting the presence of underlying novel gene pathways relevant to these phenotypes.

show abstract

Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma

Cited by 71 publications

References 33 publications

Serum total IgE levels and total eosinophil counts: relationship with treatment response in patients with acute asthma

Serum total IgE levels and total eosinophil counts: relationship with treatment response in patients with acute asthma

Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey

Gene Expression in Relation to Exhaled Nitric Oxide Identifies Novel Asthma Phenotypes with Unique Biomolecular Pathways

Contact Info

Product

Resources

About